Just about every Medicare Part D prescription drug plan on offer this year covers the original version of adalimumab (Humira), whereas only about half will pay for any of the several biosimilar ...
RIDGEFIELD, Conn. and SANTA MONICA, Calif., July 18, 2024 /PRNewswire/ -- Boehringer Ingelheim and GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., announced today a ...
The Food and Drug Administration has granted an expanded interchangeable designation for Celltrion’s Yuflyma (adalimumab-aaty), now including prefilled syringe (40mg) and autoinjectors (40mg and 80mg) ...
Alvotech and Teva have received permission from the Food and Drug Administration for Simlandi (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira, for the treatment of adult ...
(Reuters) - UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. In a unique legal challenge, the Dutch Pharmaceutical ...
Serum level of inflammatory marker C-reactive protein (CRP) predicted response to adalimumab (Humira) treatment for patients with hidradenitis suppurativa, post hoc analysis of the PIONEER I and II ...
Aug. 22, 2005 — The European Commission has approved adalimumab subcutaneous injection for the treatment of psoriatic arthritis and as first-line therapy for severe, active, and progressive rheumatoid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results